BiotechTube

Daratumumab

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Malignant Neoplasms of Male Genital Organs

Conditions

Malignant Neoplasms of Male Genital Organs, Prostate Cancer

Trial Timeline

Mar 1, 2017 → Mar 1, 2019

NCT ID
NCT03035357

About Daratumumab

Daratumumab is a phase 2 stage product being developed by Johnson & Johnson for Malignant Neoplasms of Male Genital Organs. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03035357. Target conditions include Malignant Neoplasms of Male Genital Organs, Prostate Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT03768960ApprovedCompleted
NCT03035357Phase 2Withdrawn

Competing Products

20 competing products in Malignant Neoplasms of Male Genital Organs

See all competitors
ProductCompanyStageHype Score
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + BevacizumabCSPC Pharmaceutical Group LimitedPhase 1/2
40
Fulvestrant + AbemaciclibEli LillyPhase 2
52
Tadalafil + GemcitabineEli LillyPhase 1
33
Patritumab DeruxtecanDaiichi SankyoPhase 1/2
41
Tivantinib + FOLFOXDaiichi SankyoPhase 1/2
41
DS-1123Daiichi SankyoPhase 1
33
DS-8201aDaiichi SankyoPhase 1
33
DS-5573aDaiichi SankyoPhase 1
33
DS-6051bDaiichi SankyoPhase 1
33
U3-1565Daiichi SankyoPhase 1
33
MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue MedicationsDaiichi SankyoPhase 1/2
41
DS-3201b + DS-3201bDaiichi SankyoPhase 1
33
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kgDaiichi SankyoPhase 1
33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
41
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
CP-461Astellas PharmaPhase 2
52
enfortumab vedotinAstellas PharmaPhase 1
33
LNF1901 Monoclonal Antibody InjectionSun PharmaceuticalPhase 1
33
Perampanel + Standard of CareEisaiPhase 1/2
41
Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
77

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved
85
Nicotine Gum + Nicotine PatchApproved
85
galantamineApproved
85
IbrutinibApproved
85
Paliperidone ERApproved
85